osimertinib (NCT06741085)

Name: osimertinib trial for Non Small Cell Lung Cancer Metastatic (NCT06741085)
Uploaded: 2026-10-31T05:20:09.318Z
Duration: 1 min 18 s
Description: osimertinib trial for Non Small Cell Lung Cancer Metastatic (NCT06741085). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06741085.

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain: a one-minute explainerNCT067410851 min

osimertinib trial for Non Small Cell Lung Cancer Metastatic (NCT06741085). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with EGFR-mutated non-small-cell lung cancer and brain metastases. After three months of osimertinib-based treatment, one to 20 visible, nonprogressing brain lesions must remain and be suitable for focused radiation.

The idea: compare continued drug treatment alone with added stereotactic radiosurgery. Osimertinib blocks abnormal EGFR growth signals. Focused radiation targets remaining brain tumors. Researchers measure brain progression and quality of life.

This phase 2 study plans 56 patients. Memorial Sloan Kettering leads; eight US entries list recruitment, including one data-collection-only location.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.